AIM ImmunoTech (FRA:HXB2) Other Income (Minority Interest) : €0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Other Income (Minority Interest)?

Other Income (Minority Interest) represents par value or stated value of the subsidiary stock not owned by the parent company plus the minority interest's equity in the surplus of the subsidiary. AIM ImmunoTech's Other Income (Minority Interest) for the three months ended in Dec. 2023 was €0.00 Mil. Its Other Income (Minority Interest) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.

AIM ImmunoTech Other Income (Minority Interest) Historical Data

The historical data trend for AIM ImmunoTech's Other Income (Minority Interest) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Other Income (Minority Interest) Chart

AIM ImmunoTech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Income (Minority Interest)

Get a 7-Day Free Trial

AIM ImmunoTech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Income (Minority Interest)	Get a 7-Day Free Trial															-	-	-	-	-

AIM ImmunoTech Other Income (Minority Interest) Calculation

Other Income (Minority Interest) represents par value or stated value of the subsidiary stock not owned by the parent company plus the minority interest's equity in the surplus of the subsidiary.

Other Income (Minority Interest) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

AIM ImmunoTech (FRA:HXB2) Other Income (Minority Interest) Explanation

Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company. It is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

AIM ImmunoTech (FRA:HXB2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (FRA:HXB2) » Definitions » Other Income (Minority Interest)

Comparable Companies

Traded in Other Exchanges

AIM:USA

Address

2117 SW Highway 484, Ocala, FL, USA, 34473

Website

https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (FRA:HXB2) Headlines

No Headlines